07 October 2022
ImmuPharma PLC
("ImmuPharma" or the "Company")
Appointment of Company Secretary
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm the appointment of Ward Williams Limited as Company Secretary to the Company. The appointment is with immediate effect.
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
About Ward Williams Limited
Ward Williams is a leading provider of quality business support and personal financial services. They differentiate themselves through the range of services provided. Their client-focused services are delivered through two divisions: Chartered Accountants and HR Consultants, all working together from four locations in Weybridge, Uxbridge, Sunninghill and London. For more information go to: https://www.wardwilliams.co.uk/about-us/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
